{
    "nct_id": "NCT04524611",
    "official_title": "A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF Therapy",
    "inclusion_criteria": "* Confirmed diagnosis of Crohn's disease (CD) for at least 3 months prior to Baseline.\n* Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.\n* Confirmed diagnosis of moderate to severe Crohn's Disease as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic score for CD (SES-CD).\n* Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Current diagnosis of ulcerative colitis or indeterminate colitis.\n* Receipt of CD approved biologic agents prior to Baseline (as detailed in protocol), or any investigational biologic or other agent or procedure prior to Baseline (as detailed in protocol).\n* Prior exposure to p19 and/or p40 inhibitors (e.g., risankizumab and ustekinumab).\n* Currently know complications of CD (strictures, short bowel, etc).",
    "miscellaneous_criteria": ""
}